Donepezil treatment in Alzheimer's disease patients with and without cerebrovascular lesions: a preliminary report. (Q51846639)

14 April 2018

title

Donepezil treatment in Alzheimer's disease patients with and without cerebrovascular lesions: a preliminary report. (English)

1 reference

14 April 2018

author

Hae Ri Na

1

1 reference

14 April 2018

author name string

SangYun Kim

2

1 reference

14 April 2018

Seong-Hye Choi

3

1 reference

14 April 2018

Dong-Won Yang

4

1 reference

14 April 2018

Hee-Joon Bae

5

1 reference

14 April 2018

Jung-Eun Kim

6

1 reference

14 April 2018

Mee-Young Park

7

1 reference

14 April 2018

Yong-Soo Shim

8

1 reference

14 April 2018

Byung-Kun Kim

9

1 reference

14 April 2018

Jae-Cheol Kwon

10

1 reference

14 April 2018

Bong-Goo Yoo

11

1 reference

14 April 2018

Byeong-Chae Kim

12

1 reference

14 April 2018

Jung-Seok Lee

13

1 reference

14 April 2018

publication date

3 September 2010

1 reference

14 April 2018

Geriatrics and Gerontology International

published in

1 reference

14 April 2018

volume

11

1 reference

14 April 2018

page(s)

90-97

1 reference

14 April 2018

issue

1

1 reference

14 April 2018

Atherosclerosis and AD: analysis of data from the US National Alzheimer's Coordinating Center

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0594.2010.00649.X

Clinico-neuropathological correlation of Alzheimer's disease in a community-based case series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0594.2010.00649.X

Cholinergic denervation in a pure multi-infarct state: observations on CADASIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0594.2010.00649.X

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0594.2010.00649.X

A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0594.2010.00649.X

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0594.2010.00649.X

Donepezil in vascular dementia: a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0594.2010.00649.X

Eligibility of Alzheimer's disease clinic patients for clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0594.2010.00649.X

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0594.2010.00649.X

A new rating scale for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0594.2010.00649.X

The FAB: a Frontal Assessment Battery at bedside.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0594.2010.00649.X

The Clinical Dementia Rating (CDR): current version and scoring rules

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0594.2010.00649.X

A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0594.2010.00649.X

10.1111/J.1447-0594.2010.00649.X

21 January 2018

Identifiers

DOI

1 reference

14 April 2018

PubMed ID

20825496

1 reference

14 April 2018